<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00867464</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2016-00231</org_study_id>
    <secondary_id>NCI-2016-00231</secondary_id>
    <secondary_id>999909106</secondary_id>
    <secondary_id>09-C-N106</secondary_id>
    <nct_id>NCT00867464</nct_id>
  </id_info>
  <brief_title>Extended Follow Up of Young Women in Costa Rica Who Received Vaccine Therapy for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls</brief_title>
  <official_title>Extended Follow-Up of Young Women in Costa Rica Who Received Vaccination Against Human Papillomavirus Types 16 and 18 and Unvaccinated Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research trial studies extended follow up of young women in Costa Rica who received&#xD;
      vaccine therapy for human papillomavirus types 16 and 18 and unvaccinated controls.&#xD;
      Collecting information from young women in Costa Rica who have received vaccine therapy for&#xD;
      human papillomavirus types 16 and 18 and a new group of unvaccinated controls enrolled for&#xD;
      the follow-up period, may help doctors learn more about the risks and benefits of&#xD;
      prophylactic human papillomavirus vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the 10-year global impact of human papillomavirus (HPV)-16/18 vaccination of&#xD;
      young adult women.&#xD;
&#xD;
      II. To evaluate determinants of the immune response to HPV and the vaccine, and markers of&#xD;
      long-term protection.&#xD;
&#xD;
      III. To evaluate the natural history of HPV and cervical disease in vaccinated and&#xD;
      unvaccinated populations.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Participants undergo long term follow-up comprising risk factor questionnaire, pelvic&#xD;
      examination for all sexually experienced women, and specimen collection at years 6, 8, and&#xD;
      10.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 30, 2009</start_date>
  <completion_date type="Anticipated">July 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 5, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative rate of cervical intraepithelial neoplasia 3 (CIN3)</measure>
    <time_frame>At 10 years</time_frame>
    <description>Both absolute rate differences and percent reduction in rates will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of immune response markers as prediction of long-term success of HPV vaccine</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>For efficiency, a nested case-control approach is envisioned to evaluate this question. We propose to compare women who become infected against a subset of those who do not (non-failures) with respect to immune response markers of interest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Increase in the rate of cervical lesions associated with other carcinogenic HPV types that the vaccine does not protect against from prevention of HPV-16/18 associated cervical lesions through vaccination</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>The 10-year cumulative rate of incident CIN2+ associated with HPV types other than HPV-16/18 and closely related HPV types in the alpha-7/9 species for which evidence of vaccine cross-protection is demonstrated will be compared between vaccinated and unvaccinated women.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">8670</enrollment>
  <condition>Anal Carcinoma</condition>
  <condition>Cervical Carcinoma</condition>
  <condition>Human Papillomavirus Infection</condition>
  <condition>Human Papillomavirus-Related Cervical Carcinoma</condition>
  <condition>Oral Cavity Carcinoma</condition>
  <arm_group>
    <arm_group_label>Observational (long term follow-up)</arm_group_label>
    <description>Participants undergo long term follow-up comprising risk factor questionnaire, pelvic examination for all sexually experienced women, and specimen collection at years 6, 8, and 10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cytology Specimen Collection Procedure</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Observational (long term follow-up)</arm_group_label>
    <other_name>Cytologic Sampling</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Observational (long term follow-up)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Long-term Follow-up</intervention_name>
    <description>Undergo extended follow-up</description>
    <arm_group_label>Observational (long term follow-up)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Observational (long term follow-up)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Young women in Costa Rica who received vaccination against human papillomavirus types 16&#xD;
        and 18 and unvaccinated controls.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women who participated in the Costa Rica Vaccine Trial (CVT) and lived in the&#xD;
             Guanacaste province and a few areas of Puntarenas closest to Guanacaste will be&#xD;
             eligible for the long-term follow up LTFU study&#xD;
&#xD;
          -  Women who received the HPV-16/18 vaccine at the start of CVT will be invited for up to&#xD;
             6 years of additional follow-up, and women who were originally in the control arm of&#xD;
             CVT and were offered the HPV-16/18 vaccine at crossover will be invited for an&#xD;
             additional 2 years of follow-up&#xD;
&#xD;
          -  A subset of the control arm women who are in the crossover immunogenicity subcohort&#xD;
             will be followed the full 6 years&#xD;
&#xD;
          -  Some women who received HPV vaccination and were not invited into the LTFU protocol&#xD;
             (stopped attending their screening visits during CVT, discontinued their study&#xD;
             participation during CVT or lived outside the study area) will be invited to&#xD;
             participate in the LTFU protocol, particularly those who received an incomplete&#xD;
             vaccination schedule&#xD;
&#xD;
          -  UNVACCINATED CONTROL GROUP:&#xD;
&#xD;
          -  Born in or between July 1978 and November 1987&#xD;
&#xD;
          -  Residents of Guanacaste Province and a few areas of Puntarenas closest to Guanacaste&#xD;
             at some point during 2005&#xD;
&#xD;
          -  Able to speak/understand Spanish&#xD;
&#xD;
          -  Apparently mentally competent&#xD;
&#xD;
          -  Written informed consent obtained prior to enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of cervical cancer&#xD;
&#xD;
          -  History of hysterectomy&#xD;
&#xD;
          -  Any important medical condition or other criteria that the investigator considers that&#xD;
             precludes enrollment&#xD;
&#xD;
          -  Vaccination with Gardasil or Cervarix will be an exclusionary criterion, but few women&#xD;
             are expected to have received these vaccines at the time of enrollment; use of these&#xD;
             vaccines after enrollment is not a criterion for study interruption but we plan to&#xD;
             collect information on vaccination history so that the few women who report having&#xD;
             been vaccinated with one of the HPV vaccines after enrollment can be evaluated&#xD;
             separately at analysis&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aimee Kreimer</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Agencia Costarricense de Investigaciones Biom√©dicas (ACIB)</name>
      <address>
        <city>Liberia</city>
        <state>Guanacaste</state>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Costa Rica</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 20, 2009</study_first_submitted>
  <study_first_submitted_qc>March 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2009</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

